Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit - PubMed
4 hours ago
- #heart failure
- #obesity
- #GLP-1 receptor agonists
- GLP-1 receptor agonists (GLP-1RAs) show promise in treating heart failure with preserved ejection fraction (HFpEF), especially in patients with obesity and metabolic comorbidities.
- Recent trials like STEP-HFpEF and SUMMIT highlight GLP-1RAs' benefits in improving symptoms, quality of life, and reducing heart failure events.
- GLP-1RAs contribute to weight loss and also have metabolic, cardiovascular, and anti-inflammatory effects that may benefit HFpEF patients.
- The review discusses both weight-dependent and weight-independent mechanisms of GLP-1RAs, including impacts on cardiovascular physiology, myocardial remodeling, and systemic inflammation.